ERBB2 and neoplasm: Our light-activated antibody drug conjugate has shown tumour regression in an in vivo animal model replicating borderline but negative HER2 heterogeneity so could offer an alternative therapeutic option for the large number of patients that are HER2 positive or borderline negative, patients with localised disease that are unfit for curative resection or patients who have relapsed after first-line therapy.